0.35Open0.35Pre Close0 Volume2 Open Interest30.00Strike Price0.00Turnover306.11%IV202.29%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.1273Delta0.0286Gamma28.69Leverage Ratio-0.0365Theta0.0005Rho3.65Eff Leverage0.0050Vega
TYRA BIOSCIENCES, INC. Stock Discussion
Tyra Bio Achieves 54.5% Response Rate in Cancer Trial, Secures 3-Year Runway
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$